Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients

Francesco Boccardo, A. Rubagotti, M. Battaglia, F. Zattoni, A. Bertaccini, A. Romagnoli, G. Conti

Research output: Contribution to journalArticle

Abstract

Background: There is growing evidence that IGF-1 and binding proteins may be involved in prostate cancer promotion and progression. Patients and methods: IGF-1 and binding proteins (IGFBP-1 and 3) serum levels were measured at baseline and after 3 and 6 months of treatment in a selected group of patients with prostate cancer who were randomly assigned to treatment with bicalutamide, bicalutamide plus anastrozole or bicalutamide plus tamoxifen in a comparative study investigating the role of pharmacological medication in the development of bicalutamide-induced gynecomastia. Results: Bicalutamide monotherapy does not appear to alter the IGF-1/ IGFBP system. In fact, the increase in IGF-1 levels induced by this treatment was paralleled by comparable increases in binding protein (IGFBP-3). No major changes from baseline up to month 6 either in IGF-1 or in IGFBP-1 and 3 were observed in the bicalutamide plus anastrozole arm. The addition of tamoxifen to bicalutamide produced a sharp decrease in IGF-1 levels (p

Original languageEnglish
Pages (from-to)123-126
Number of pages4
JournalInternational Journal of Biological Markers
Volume21
Issue number2
Publication statusPublished - Apr 2006

Keywords

  • Anastrozole
  • Antiandrogen monotherapy
  • IGF binding proteins
  • IGF-1
  • Prostate cancer
  • Tamoxifen

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Fingerprint Dive into the research topics of 'Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients'. Together they form a unique fingerprint.

  • Cite this